SciSparc Ltd. (formerly Therapix Biosciences Ltd.) is a well-respected clinical-stage cannabis company that operates within the biopharmaceutical industry. Based in Israel, this specialty company is primarily focused on developing advanced drug products that are based on cannabinoid molecules, a class of diverse chemical compounds found within the cannabis plant.
SciSparc holds a strong commitment to research and development and is presently working on a range of medical treatments. Their research involves manufacturing pharmaceutical-grade THC, the psychoactive compound in cannabis. Their development strategy includes preclinical and clinical-stage programs, focused on disorders of the central nervous system (CNS).
The company’s leading proprietary drug candidate, THX-110, is centred on the therapeutic effects of dronabinol (synthetic THC). This drug candidate is currently being evaluated across several CNS-related clinical trials, including a Phase IIa study for the treatment of Obstructive Sleep Apnea (OSA) and a pilot clinical trial for the treatment of Tourette syndrome.
In addition to THC-based products, SciSparc is also involved in the development of new methods and technologies to enhance the bioavailability of cannabinoids. The company has various other products in its pipeline, including THX-150, for the treatment of infectious diseases, and THX-130, for the treatment of mild cognitive impairment (MCI) and traumatic brain injury.
The company operates its robust R&D activity under the management of an impressive, cross-disciplinary team of experienced professionals, including medical practitioners, scientists, and pharmaceutical-industry veterans. This team is responsible for pushing innovative drug candidates through the development pipeline, ensuring that they meet the standards set by international regulatory bodies.
SciSparc trades on the NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol SPRC. The company, which has a market capitalization of $3 million, is shareholder-funded and is continually striving to create the best possible results for its investors.
Facing emerging regulatory and legal challenges worldwide, SciSparc remains committed to its vision of advancing the use of cannabinoids for therapeutic purposes. They strive for excellence in their R&D activities, staying aligned with global best practices and international regulations. This integrity, combined with its innovative approach to drug development, ensures that SciSparc continues to pave the way within the global cannabinoid pharmaceutical market.